0001415889-24-020475.txt : 20240731
0001415889-24-020475.hdr.sgml : 20240731
20240731193120
ACCESSION NUMBER: 0001415889-24-020475
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240729
FILED AS OF DATE: 20240731
DATE AS OF CHANGE: 20240731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hohl Benjamin
CENTRAL INDEX KEY: 0001882764
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39247
FILM NUMBER: 241163535
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Enliven Therapeutics, Inc.
CENTRAL INDEX KEY: 0001672619
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811523849
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-647-8519
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: IMARA Inc.
DATE OF NAME CHANGE: 20160419
4
1
form4-07312024_110716.xml
X0508
4
2024-07-29
0001672619
Enliven Therapeutics, Inc.
ELVN
0001882764
Hohl Benjamin
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
BOULDER
CO
80301
false
true
false
false
CHIEF FINANCIAL OFFICER
1
Common Stock
2024-07-29
4
M
0
5250
2.48
A
5250
D
Common Stock
2024-07-29
4
S
0
5189
26.6676
D
61
D
Common Stock
2024-07-29
4
S
0
61
27.4431
D
0
D
Stock Option (right to buy)
2.48
2024-07-29
4
M
0
5250
0
D
2031-08-02
Common Stock
5250
204370
D
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
This transaction was executed in multiple trades at prices ranging from $26.34 to $27.3359. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $27.41 to $27.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.
/s/ Benjamin Hohl
2024-07-31